An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer

NCT03915951

Last updated date
Study Location
UCLA - Westwood
Los Angeles, California, 90095, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-small Cell Lung Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is currently Stage IV.

- Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay.

- Patients who are either treatment-naïve (e.g., no prior systemic therapy for advanced/metastatic disease), OR who have received 1) first-line platinum-based chemotherapy OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/ programmed cell death protein ligand 1(PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy.

- Presence of measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

- Eastern Cooperation Oncology Group (ECOG) performance status of 0 or 1.

- Adequate bone marrow function characterized by the following at screening:

- absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L;

- Platelets ≥ 100 × 10⁹/L;

- Hemoglobin ≥ 8.5 g/dL (with or without blood transfusions).

- Adequate hepatic and renal function characterized by the following at screening:

- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)

- alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN, or ≤ 5 × ULN in presence of liver metastases; Serum creatinine ≤ 1.5 × ULN; or calculated creatinine clearance ≥ 50 mL/min by Cockcroft-Gault formula; or estimated glomerular filtration rate > 50 mL/min/1.73m².

Key

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who have documentation of any of the following:


- epidermal growth factor receptor (EGFR) mutation


- anaplastic lymphoma kinase (ALK) fusion oncogene or


- ROS1 rearrangement


- Patients who have received more than 1 prior line of systemic therapy in the
advanced/metastatic setting.


- Previous treatment with any BRAF inhibitor (e.g., dabrafenib, vemurafenib,
XL281/BMS-908662, etc.), or any mitogen-activated protein kinase (MEK) inhibitor
(e.g., trametinib, cobimetinib, selumetinib, RDEA119, etc.) prior to screening and
enrollment.


- Impaired cardiovascular function or clinically significant cardiovascular diseases


- History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose
of study treatment. Examples include transient ischemic attacks, cerebrovascular
accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein
thrombosis or pulmonary emboli.


- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
or hypercoagulability syndromes); history of retinal degenerative disease.


- Concurrent neuromuscular disorder that is associated with the potential of elevated
creatine (phospho)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy,
amyotrophic lateral sclerosis, spinal muscular atrophy).


- Patients with symptomatic brain metastasis, leptomeningeal disease or other active
central nervous system (CNS) metastases are not eligible.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
NCT02920450
  1. Gainesville, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
NCT00300729
  1. Gothenburg,
  2. Jönköping,
  3. Kalmar,
  4. Linköping,
  5. Lund,
  6. Malmö,
  7. Skövde,
  8. Trollhättan,
  9. Uddevalla,
  10. Umeå,
  11. Uppsala,
  12. Ystad,
  13. Örebro,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT00555256
  1. St. Louis, Missouri
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
NCT03915951
  1. Los Angeles, California
  2. Santa Monica, California
  3. Norwich, Connecticut
  4. Putnam, Connecticut
  5. Lady Lake, Florida
  6. Venice, Florida
  7. Overland Park, Kansas
  8. Baltimore, Maryland
  9. Baltimore, Maryland
  10. Boston, Massachusetts
  11. Boston, Massachusetts
  12. Boston, Massachusetts
  13. Boston, Massachusetts
  14. Boston, Massachusetts
  15. Chelsea, Massachusetts
  16. Danvers, Massachusetts
  17. Marlborough, Massachusetts
  18. Stoneham, Massachusetts
  19. Waltham, Massachusetts
  20. Independence, Missouri
  21. Independence, Missouri
  22. Kansas City, Missouri
  23. Kansas City, Missouri
  24. Basking Ridge, New Jersey
  25. Montvale, New Jersey
  26. Bronx, New York
  27. Bronx, New York
  28. New York, New York
  29. New York, New York
  30. New York, New York
  31. Columbus, Ohio
  32. Clackamas, Oregon
  33. Newberg, Oregon
  34. Portland, Oregon
  35. Pittsburgh, Pennsylvania
  36. Pittsburgh, Pennsylvania
  37. Pittsburgh, Pennsylvania
  38. Pittsburgh, Pennsylvania
  39. York, Pennsylvania
  40. Chattanooga, Tennessee
  41. Hendersonville, Tennessee
  42. Houston, Texas
  43. Shenandoah, Texas
  44. Faenza, Emilia-romagna
  45. Lugo, Emilia-romagna
  46. Ravenna, Emilia-romagna
  47. Rimini, Emilia-romagna
  48. Milano, Lombardia
  49. Torino, Piemonte
  50. Cattolica, Rimini
  51. Orbassano, Torino
  52. Milano,
  53. Naples,
  54. Amsterdam, Noord-holland
  55. Hospitalet de Llobregat, Barcelona
  56. L'Hospitalet de Llobregat, Barcelona
  57. L'Hospitalet de Llobregat, Barcelona
  58. L'Hospitalet de Llobregat, Barcelona
  59. Barcelona,
  60. Barcelona,
  61. Hospitalet de Llobregat,
  62. Sevilla,
  63. Norwich, Connecticut
  64. Fort Myers, Florida
  65. Saint Petersburg, Florida
  66. Tallahassee, Florida
  67. Atlanta, Georgia
  68. Baltimore, Maryland
  69. Boston, Massachusetts
  70. Boston, Massachusetts
  71. Boston, Massachusetts
  72. Stoneham, Massachusetts
  73. Saint Louis, Missouri
  74. Hackensack, New Jersey
  75. Bronx, New York
  76. New York, New York
  77. New York, New York
  78. Durham, North Carolina
  79. Columbus, Ohio
  80. Portland, Oregon
  81. York, Pennsylvania
  82. Chattanooga, Tennessee
  83. Nashville, Tennessee
  84. Houston, Texas
  85. Seattle, Washington
  86. Ravenna, Emilia-romagna
  87. Milano, Lombardia
  88. Napoli, Naples
  89. Bologna,
  90. Goyang-si, Gyeonggido
  91. Jeonnam,
  92. Seoul,
  93. Seoul,
  94. Seoul,
  95. Amsterdam, Noord-holland
  96. Groningen,
  97. Majadahonda, Madrid
  98. Malaga, Málaga
  99. Barcelona,
  100. Barcelona,
  101. Barcelona,
  102. Córdoba,
  103. Madrid,
  104. Madrid,
  105. Sevilla,
  106. Sevilla,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
Official Title  ICMJE A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
Brief Summary This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treatment-naïve, OR who have received 1) first-line treatment with standard platinum-based chemotherapy, OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy will be enrolled.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Non-small Cell Lung Cancer
Intervention  ICMJE
  • Drug: encorafenib
    self-administered orally
  • Drug: binimetinib
    self-administered orally
Study Arms  ICMJE Experimental: Treatment Period

Study treatment with encorafenib and binimetinib will be self-administered orally without regard to food.

Patients will receive the following per 28-day (± 3 days) cycle:

  • Encorafenib: 450 mg (6 × 75 mg capsule) once daily (QD)
  • Binimetinib: 45 mg (3 × 15 mg tablet) twice daily (BID)
Interventions:
  • Drug: encorafenib
  • Drug: binimetinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 12, 2019)
40
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 24, 2023
Estimated Primary Completion Date March 31, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) that is currently Stage IV.
  • Presence of a BRAFV600E mutation in lung cancer tissue as determined by a local laboratory assay.
  • Patients who are either treatment-naïve (e.g., no prior systemic therapy for advanced/metastatic disease), OR who have received 1) first-line platinum-based chemotherapy OR 2) first-line treatment with an anti-programmed cell death protein 1 (PD-1)/ programmed cell death protein ligand 1(PD-L1) inhibitor given alone or in combination with platinum-based chemotherapy.
  • Presence of measurable disease based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
  • Eastern Cooperation Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate bone marrow function characterized by the following at screening:

    • absolute neutrophil count (ANC) ? 1.5 × 10?/L;
    • Platelets ? 100 × 10?/L;
    • Hemoglobin ? 8.5 g/dL (with or without blood transfusions).
  • Adequate hepatic and renal function characterized by the following at screening:

    • Total bilirubin ? 1.5 × upper limit of normal (ULN)
    • alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 × ULN, or ? 5 × ULN in presence of liver metastases; Serum creatinine ? 1.5 × ULN; or calculated creatinine clearance ? 50 mL/min by Cockcroft-Gault formula; or estimated glomerular filtration rate > 50 mL/min/1.73m².

Key Exclusion Criteria:

  • Patients who have documentation of any of the following:

    • epidermal growth factor receptor (EGFR) mutation
    • anaplastic lymphoma kinase (ALK) fusion oncogene or
    • ROS1 rearrangement
  • Patients who have received more than 1 prior line of systemic therapy in the advanced/metastatic setting.
  • Previous treatment with any BRAF inhibitor (e.g., dabrafenib, vemurafenib, XL281/BMS-908662, etc.), or any mitogen-activated protein kinase (MEK) inhibitor (e.g., trametinib, cobimetinib, selumetinib, RDEA119, etc.) prior to screening and enrollment.
  • Impaired cardiovascular function or clinically significant cardiovascular diseases
  • History of thromboembolic or cerebrovascular events ? 12 weeks prior to the first dose of study treatment. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes); history of retinal degenerative disease.
  • Concurrent neuromuscular disorder that is associated with the potential of elevated creatine (phospho)kinase (CK) (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • Patients with symptomatic brain metastasis, leptomeningeal disease or other active central nervous system (CNS) metastases are not eligible.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pfizer Pfizer CT.gov Call Center1-800-718-1021[email protected]
Listed Location Countries  ICMJE Italy,   Korea, Republic of,   Netherlands,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03915951
Other Study ID Numbers  ICMJE ARRAY-818-202
C4221008 ( Other Identifier: Alias Study Number )
2019-000417-37 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP